ArticleJournal of applied genetics2026
Clinical whole exome sequencing in childhood epilepsy: a tertiary center retrospective study from Saudi Arabia.
Article in Journal of applied genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Childhood epilepsy, particularly when drug-resistant, often has an underlying genetic etiology. Populations with high consanguinity rates, such as Saudi Arabia, are expected to have a higher burden of autosomal recessive disorders. However, the diagnostic yield and clinical utility of whole-exome sequencing (WES) in this context require further characterization. We conducted a retrospective cross-sectional study at King Faisal Specialist Hospital and Research Centre-Jeddah (KFSHRC-J) between May 2017 and November 2021. We reviewed charts of all patients with clinical WES results (n = 561) and included 108 pediatric patients (< 14 years) for whom epilepsy was the primary indication for testing. Data on demographics, clinical presentation, radiological findings, and WES results were extracted from electronic medical records. Variants were classified according to ACMG guidelines. Among 108 patients (53 males, 49%; 55 females, 51%), the mean age at epilepsy onset was 2.6 years, and 77% (83/108) reported consanguinity. WES identified reportable genetic findings in 98 cases (90.7%), classified as pathogenic/likely pathogenic variants (n = 32) or variants of unknown significance (VUS) (n = 66). In the remaining 10 cases (9.3%), no variant considered sufficient to explain the clinical phenotype was identified. The definitive diagnostic yield, defined as pathogenic or likely pathogenic variants explaining the clinical phenotype, was 30% (32/108; 95% CI: 22-39%). Autosomal recessive inheritance accounted for 72% (23/32) of diagnosed cases. When including VUS with strong phenotype correlation, the potential diagnostic yield increased to 60% (65/108). WES results directly influenced clinical management in 5% (5/108) of patients, including targeted metabolic therapy, medication optimization, and avoidance of contraindicated therapies. WES demonstrates significant diagnostic utility in childhood epilepsy, particularly in consanguineous populations with a high burden of autosomal recessive disorders. Integration of WES into the diagnostic workflow enables precision medicine approaches and supports early genetic counseling.
Indexed as
Identifiers
42897344What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.